pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
fda recalls·1d ago·1 min read
save

SUPPLX.com recalls two male sexual-enhancement supplements after FDA finds undeclared yohimbine

Sep 3, 2026·read at fda recalls ↗CRLNegative

SUPPLX.com announced a voluntary recall of its Business Pill and Branch Manager for Men supplements after FDA laboratory analysis detected undeclared yohimbine in both products.

Yohimbine is a prescription‑only alkaloid associated with serious cardiovascular risks, including severe hypertension, tachycardia, arrhythmia and heart attacks, particularly when taken with other stimulants.

The FDA warned that the recalled products can also cause severe gastrointestinal distress and acute neurological effects. Consumers are urged to stop using the supplements and return them for a refund.

source

This writeup was produced by pharmadog from original reporting by fda recalls.

Original headline: “SUPPLX.com Issues Voluntary Nationwide Recall of Business Pill and Branch Manager for Men Due to Undeclared Yohimbine”

read at fda recalls ↗
427 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

drugs
caffeine
topics
Recall8Cardiology3Hypertension2EpilepsyHematologyNeurologyPain

related stories

  • 2h agoTScan axes 75% of workforce, prioritizes solid tumor programBioSpace
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Jun 1The hidden history of BPC-157, a favorite MAHA peptideSTAT
  • 3d agoNew guidelines on migraine prevention reflect increasing options for patientsSTAT
  • Aug 27Ana Salazar Modela Tu Cuerpo Inc. Issues Nationwide Voluntary Recall of Lipofit Extreme Fat Burner 2.0 Due to Presence of Undeclared Fluoxetine and 2,4-Dinitrophenol (DNP)fda recalls